Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965 · see citing works

Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease

Eddowes, P. J., Sasso, M., Allison, M., Tsochatzis, E. A., Anstee, Q. M., Sheridan, D. A., Guha, I. N., Cobbold, J., Deeks, J. J., Paradis, V., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.042 · Cited by 1,425 · see citing works

Diagnosis of Fibrosis and Cirrhosis Using Liver Stiffness Measurement in Nonalcoholic Fatty Liver Disease

Wong, V. W.-S., Vergniol, J., Wong, G. L.-H., Foucher, J., Chan, H. L.-Y., Le Bail, B., Choi, P. C.-L., Kowo, M., Chan, A. W.-H., Merrouche, W., et al. (2010) · Hepatology · doi:10.1002/hep.23312 · Cited by 1,322 · see citing works

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277 · see citing works

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035 · see citing works

Optimal threshold of controlled attenuation parameter with MRI‐PDFF as the gold standard for the detection of hepatic steatosis

Caussy, C., Alquiraish, M. H., Nguyen, P., Hernandez, C., Cepin, S., Fortney, L., Ajmera, V. H., Bettencourt, R., Collier, S., Hooker, J. C., et al. (2017) · Hepatology · doi:10.1002/hep.29639 · Cited by 378 · see citing works

Transient elastography (FibroScan ^® ) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?

Mikolasevic, I., Orlic, L., Franjic, N., Hauser, G., Stimac, D., & Milic, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7236 · Cited by 273 · see citing works

Dual PPAR α/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

Jain, M. R., Giri, S. R., Bhoi, B., Trivedi, C. J., Rath, A., Rathod, R., Ranvir, R. K., Kadam, S. B., Patel, H., Swain, P. K., et al. (2017) · Liver International · doi:10.1111/liv.13634 · Cited by 207 · see citing works

Non-alcoholic Fatty Liver Disease and Metabolic Syndrome—Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology

Duseja, A. K., Singh, S. P., Saraswat, V. A., Acharya, S. K., Chawla, Y. K., Chowdhury, S., Dhiman, R. K., Jayakumar, R. V., Madan, K., Misra, S. P., et al. (2015) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2015.02.006 · Cited by 186 · see citing works

Application of transient elastography in nonalcoholic fatty liver disease

Zhang, X., Wong, G. L., & Wong, V. W. (2019) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2019.0001n · Cited by 138 · see citing works

A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)

Jani, R. H., Pai, V., Jha, P. R., Jariwala, G., Mukhopadhyay, S., Bhansali, A. K., & Joshi, S. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.0253 · Cited by 118 · see citing works

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease

Kumar, D. P., Caffrey, R., Marioneaux, J., Santhekadur, P. K., Bhat, M., Alonso, C., Koduru, S. V., Philip, B., Jain, M. R., Giri, S. R., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-66458-z · Cited by 116 · see citing works

A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V)

Pai, V., Paneerselvam, A., Mukhopadhyay, S., Bhansali, A. K., Kamath, D., Shankar, V., Gambhire, D., Jani, R. H., Joshi, S., & Patel, P. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296813518680 · Cited by 115 · see citing works

Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients

Garg, H., Aggarwal, S., Shalimar, S., Yadav, R., Gupta, S. D., Agarwal, L., & Agarwal, S. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.09.005 · Cited by 112 · see citing works

Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial

Anushiravani, A., Haddadi, N., Pourfarmanbar, M., & Mohammadkarimi, V. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001369 · Cited by 107 · see citing works

Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels

Gawrieh, S., Wilson, L., Cummings, O. W., Clark, J. M., Loomba, R. S., Hameed, B., Abdelmalek, M. F., Dasarathy, S., Neuschwander‐Tetri, B. A., Kowdley, K. V., et al. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000388 · Cited by 97 · see citing works

The Diagnostic Accuracy of Transient Elastography for the Diagnosis of Liver Fibrosis in Bariatric Surgery Candidates with Suspected NAFLD

Naveau, S., Lamouri, K., Pourcher, G., Njiké‐Nakseu, M., Ferretti, S., Courie, R., Tranchart, H., Ghinoiu, M., Balian, A., Prevot, S., et al. (2014) · Obesity Surgery · doi:10.1007/s11695-014-1235-9 · Cited by 88 · see citing works

Lipid Management in Type 2 Diabetes

Solano, M. P., & Goldberg, R. B. (2006) · Clinical Diabetes · doi:10.2337/diaclin.24.1.27 · Cited by 80 · see citing works

Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease

Choudhary, N. S., Kumar, N., & Duseja, A. K. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.06.004 · Cited by 74 · see citing works

Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials

Connolly, J. J., Ooka, K., & Lim, J. K. (2018) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2017.00056 · Cited by 58 · see citing works

A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis

Jun, B. G., Park, W. Y., Park, E. J., Jang, J. Y., Jeong, S. W., Lee, S. H., Kim, S. G., Cha, S., Kim, Y. S., Cho, Y. D., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182784 · Cited by 49 · see citing works

Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial

Jain, N., Bhansali, S., Kurpad, A. V., Hawkins, M. A., Sharma, A. D., Kaur, S., Rastogi, A., & Bhansali, A. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-55466-3 · Cited by 49 · see citing works

Observational study to evaluate the safety and efficacy of saroglitazar in Indian diabetic dyslipidemia patients

Shetty, S., Kumar, S., Mathur, R. P., Sharma, K. H., & Jaiswal, A. D. (2015) · Indian Heart Journal · doi:10.1016/j.ihj.2015.02.007 · Cited by 43 · see citing works

Observational Study of Effects of Saroglitazar on Glycaemic and Lipid Parameters on Indian Patients with Type 2 Diabetes

Chatterjee, S., Majumder, A., & Ray, S. (2015) · Scientific Reports · doi:10.1038/srep07706 · Cited by 42 · see citing works

An update on the pharmacological treatment of nonalcoholic fatty liver disease: Beyond lifestyle modifications

Alkhouri, N., & Scott, A. L. (2018) · Clinical Liver Disease · doi:10.1002/cld.708 · Cited by 41 · see citing works

Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India.

Pathik, P., Ravindra, S., Choksey, A. S., Prasad, B., Jatin, P., & Prabha, S. (2015) · PubMed Central · Cited by 40 · see citing works

HbA1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels

Chen, C., Zhu, Z., Mao, Y., Xu, Y., Du, J., Tang, X., & Cao, H. (2020) · Bioscience Reports · doi:10.1042/bsr20193996 · Cited by 34 · see citing works

Noninvasive chimeric DNA profiling identifies tumor-originated HBV integrants contributing to viral antigen expression in liver cancer

Chen, W., Zhang, K., Dong, P., Fanning, G. C., Tao, C., Zhang, H., Guo, S., Wang, Z., Hong, Y., Yang, X., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10016-2 · Cited by 29 · see citing works

Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis

Lee, J. I., Lee, H. W., & Lee, K. S. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i33.4959 · Cited by 21 · see citing works

Obser vational Study of Saroglitazar on Metabolic Parameters in Indian Patients with Diabetic Dyslipidaemia – A Fifty Eight Weeks of Clinical Experience

Chatterjee, S. (2018) · Diabetes & Obesity International Journal · doi:10.23880/doij-16000180 · Cited by 7 · see citing works

A Heterozygous ABCB4, RUNDC3B, and ABCB1 Deletion Associated With Severe Cholestatic Liver Disease in Adulthood

Beretta‐Piccoli, B. T., Thompson, R. J., Foskett, P., Cerny, A., Merlo, E., Vergani, D., Rougemont, A., Moix, I., Mieli‐Vergani, G., & Morris, M. A. (2019) · Hepatology · doi:10.1002/hep.30783 · Cited by 6 · see citing works

A Prospective, Multicentre, Single Arm Clinical Study to Evaluate the Effect of Saroglitazar on Non High-Density Lipoprotein Cholesterol in Patients with Diabetic Dyslipidemia Inadequately Controlled with Diet, Exercise, and Statin-The GLIDDER Study

Kaul, U., Arambam, P., Kachru, R., Bhatia, V., Yumnam, D., ungla, N., Shah, M., Parmar, K., Jaiswal, A. D., & Jain, P. (2019) · doi:10.35248/2155-6156.19.10.819 · Cited by 5 · see citing works

Abstract #1311: Saroglitazar in Non-Alcoholic Fatty Liver Disease

Joshi, S., Sound, R., Saboo, B., Chawla, R., & Bhandari, S. (2016) · Endocrine Practice · doi:10.1016/s1530-891x(20)44880-3 · Cited by 5 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210 · see citing works

EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 510 · see citing works

Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways

Badmus, O. O., Hillhouse, S. A., Anderson, C. D., Hinds, T. D., & Stec, D. E. (2022) · Clinical Science · doi:10.1042/cs20220572 · Cited by 372 · see citing works

Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)

Duseja, A. K., Singh, S. P., De, A., Madan, K., Rao, P. N., Shukla, A., Choudhuri, G., Saigal, S., Shalimar, S., Arora, A., et al. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.11.014 · Cited by 105 · see citing works

Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease

Badmus, O. O., Hinds, T. D., & Stec, D. E. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01242-8 · Cited by 87 · see citing works

PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients

Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 81 · see citing works

Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis

Vuppalanchi, R., Caldwell, S. H., Pyrsopoulos, N., deLemos, A. S., Rossi, S., Levy, C., Goldberg, D. S., Mena, E. A., Sheikh, A., Ravinuthala, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.025 · Cited by 79 · see citing works

Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches

Radosavljević, T. S., Branković, M., Samardžić, J., Djuretić, J., Vukićević, D., Vučević, D. B., & Jakovljevic, V. L. (2024) · Antioxidants · doi:10.3390/antiox13080906 · Cited by 76 · see citing works

Hepatic insulin receptor: new views on the mechanisms of liver disease

Lee, W., Najjar, S. M., Kahn, C. R., & Hinds, T. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155607 · Cited by 69 · see citing works

Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies

Qu, W., Ma, T., Cai, J., Zhang, X., Zhang, P., She, Z., Wan, F., & Li, H. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.761538 · Cited by 68 · see citing works

An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes

Giglio, R. V., Παπάνας, Ν., Rizvi, A. A., Ciaccio, M., Patti, A. M., Ilias, Ι., Stoian, A. P., Sahebkar, A., Janež, A., & Rizzo, M. (2022) · Medicina · doi:10.3390/medicina58101475 · Cited by 67 · see citing works

Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD

Ezhilarasan, D. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155912 · Cited by 53 · see citing works

Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates

Александровна, П. В., Bezborodkina, N. N., & Okovityi, S. V. (2022) · Biomedicines · doi:10.3390/biomedicines10020274 · Cited by 52 · see citing works

MASLD treatment—a shift in the paradigm is imminent

Machado, M. V. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1316284 · Cited by 51 · see citing works

Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond

Soto, A., Spongberg, C. V., Martinino, A., & Giovinazzo, F. (2024) · Biomedicines · doi:10.3390/biomedicines12020397 · Cited by 50 · see citing works

Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis

Akbari, R., Behdarvand, T., Afarin, R., Yaghooti, H., Jalali, M. T., & Mohammadtaghvaei, N. (2021) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-021-00524-8 · Cited by 40 · see citing works

Efficacy and safety of saroglitazar in real‐world patients of non‐alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience

Chaudhuri, S., Dutta, A., & Chakraborty, S. B. D. (2023) · JGH Open · doi:10.1002/jgh3.12878 · Cited by 38 · see citing works

Effects of saroglitazar in the treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis: A systematic review and meta-analysis

Bandyopadhyay, S. K., Samajdar, S. S., & Das, S. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102174 · Cited by 35 · see citing works

Hepatocyte CYR61 polarizes profibrotic macrophages to orchestrate NASH fibrosis

Mooring, M., Yeung, G. A., Luukkonen, P., Liu, S., Akbar, M. W., Zhang, G. J., Balogun, O., Yu, X., Mo, R., Nejak-Bowen, K., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade3157 · Cited by 33 · see citing works

Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate

Honda, A., Kamata, S., Akahane, M., Machida, Y., Uchii, K., Shiiyama, Y., Habu, Y., Miyawaki, S., Kaneko, C., Oyama, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094726 · Cited by 32 · see citing works

Trilobatin alleviates non-alcoholic fatty liver disease in high-fat diet plus streptozotocin-induced diabetic mice by suppressing NLRP3 inflammasome activation

Zhang, Z., He, W.-J., Deng, S., Xu, S.-H., Zeng, X., Qian, Z., Chen, Z., Wang, S., & Tang, D. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175291 · Cited by 30 · see citing works

Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients

Padole, P., Arora, A., Sharma, P., Chand, P., Verma, N., & Kumar, A. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.06.015 · Cited by 28 · see citing works

Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids

Sarkar, S., Kumari, D., Gupta, S. K., Sharma, V., Mukhi, S., Kamboj, P., Vedula, S., Rai, R. K., Jatavallabhula, S. L., Mahajan, D., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112357 · Cited by 27 · see citing works

The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018

Bae, J. C., Beste, L. A., & Utzschneider, K. M. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1434 · Cited by 27 · see citing works

The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis

Mo, M.-Q., Huang, Z., Liang, Y., Liao, Y., & Xia, N. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.08.017 · Cited by 26 · see citing works

Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease

Teng, T., Qiu, S., Zhao, Y., Zhao, S., Sun, D., Hou, L., Li, Y., Zhou, K., Yu, X., Yang, C., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147841 · Cited by 26 · see citing works

Saroglitazar, a dual PPAR-α/γ agonist, alleviates LPS-induced hepatic and renal injury in rats

Francis, M. R., El‐Sheakh, A. R., & Suddek, G. M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109688 · Cited by 25 · see citing works

Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease

Brown, E. E., Hydes, T., Hamid, A., & Cuthbertson, D. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.013 · Cited by 24 · see citing works

Emerging pharmacological treatment options for MAFLD

Rojas, Á., Lara, C., Múñoz‐Hernández, R., Gato, S., Ampuero, J., & Romero‐Gómez, M. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221142452 · Cited by 24 · see citing works

Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease

Bołdys, A., Bułdak, Ł., Maligłówka, M., Surma, S., & Okopień, B. (2023) · Medicina · doi:10.3390/medicina59101789 · Cited by 23 · see citing works

A Prospective Randomised Comparative Four-arm Intervention Study of Efficacy and Safety of Saroglitazar and Vitamin E in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH)-SVIN TRIAL

Mir, B. A., Sharma, R., Sharma, R., Bodh, V., Chauhan, A., Majeed, T., Haq, I., Sharma, N., & Sharma, D. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.101398 · Cited by 17 · see citing works

Nanomedicine targeting PPAR in adipose tissue macrophages improves lipid metabolism and obesity-induced metabolic dysfunction

Applegate, C. C., Kang, Y., Deng, H., Chen, D., Medina, N. G., Cui, Y., Feng, Y., Kuo, C.-W., Shahoei, S. H., Kim, H., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads3731 · Cited by 15 · see citing works

Altered lipid metabolism and the development of metabolic-associated fatty liver disease

Foster, C., Gagnon, C. A., & Ashraf, A. P. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000933 · Cited by 19 · see citing works

Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis

Vijayakumar, A., Ökesli, A., Wang, T., Olson, I. A., Seung, M., Kusam, S., Hollenback, D., Mahadevan, S., Marchand, B., Toteva, M. M., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.2011 · Cited by 14 · see citing works

Lipid-Lowering Responses to Dyslipidemia Determine the Efficacy on Liver Enzymes in Metabolic Dysfunction-Associated Fatty Liver Disease with Hepatic Injuries: A Prospective Cohort Study

Liao, X., Ma, Q., Wu, T., Shao, C., Lin, Y., Sun, Y., Feng, S., Wang, W., Ye, J., & Zhong, B. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s356371 · Cited by 14 · see citing works

Unraveling the Potential Role of Tecomella undulata in Experimental NASH

Srinivas, A. N., Suresh, D., Suvarna, D., Pankaj, P., Giri, S. R., Suman, Satish, S., Chidambaram, S. B., & Kumar, D. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043244 · Cited by 14 · see citing works

Peroxisome proliferator-activated receptors (PPARs) agonists as promising neurotherapeutics

Ghannam, I. A. Y., Hassan, R. M., & Abdel‐Maksoud, M. S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108226 · Cited by 12 · see citing works

Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension

Kalo, E., Read, S. A., & Ahlenstiel, G. (2021) · Livers · doi:10.3390/livers1030014 · Cited by 12 · see citing works

Faecal microbiota transplantation is better than probiotics for tissue regeneration of type 2 diabetes mellitus injuries in mice

Wang, Y., Yang, Z., Tang, H., Sun, X., Qu, J., Lu, S., & Rao, B. (2022) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2022.2080229 · Cited by 12 · see citing works

A scientifically validated combination of garcinol, curcuminoids, and piperine for mild to moderate nonalcoholic steatohepatitis patients—results from a randomized, double-blind, placebo-controlled study

Majeed, M. A., Nagabhushanam, K., Noureddin, M., Paulose, S., Barik, C., Saklecha, S., & Mundkur, L. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1201186 · Cited by 10 · see citing works

Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis

Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 9 · see citing works

Saroglitazar in Non-alcoholic Fatty Liver Disease From Bench to Bedside: A Comprehensive Review and Sub-group Meta-Analysis

Roy, A., Tewari, B., Giri, S., & Goenka, M. K. (2023) · Cureus · doi:10.7759/cureus.47493 · Cited by 9 · see citing works

Efficacy and Safety of Saroglitazar in Patients with Cardiometabolic Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Durga, D. R., Mounika, N., Mudimala, P., & Adela, R. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01219-6 · Cited by 8 · see citing works

Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients

Panuganti, V. K., Alluri, C. V., Mohammad, J., Dundigalla, M. R., Madala, P. K., KSSVV, S., & shaik, A. H. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i12.113658 · Cited by 6 · see citing works

Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC)

Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 6 · see citing works

Evaluation of Effectiveness and Tolerability of Saroglitazar in Metabolic Disease Patients of India: A Retrospective, Observational, Electronic Medical Record-Based Real-World Evidence Study

Das, S., Gupta, S. K., Lathia, T. B., Swain, J., Mittal, S., Kumar, S., Dm, M., Garg, N., Teja, R., Beatrice, A., et al. (2025) · Cureus · doi:10.7759/cureus.89028 · Cited by 5 · see citing works

Dual PPRαϒ Agonists for the Management of Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Menezes, A. D. S., Oliveira, V. M. R., Oliveira, I. C., de Sousa, A. M., Santana, A. J. P., Carvalho, D. P. C., Piai, R. F. P., Matos, F. H., de Paiva, A. M., & Reis, G. B. B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175674 · Cited by 4 · see citing works

Do Hepatic Fibrosis and Steatosis Measured by Hepatic Transient Elastography (FibroScan) Predict Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease: An Observational Cross-sectional Study

Goyal, P., Chopra, R., & Goyal, O. (2024) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_2_2024 · Cited by 4 · see citing works

Suppression of TGF-β/Smad3 signaling pathway by Capparis spinosa and quercetin in a rat model of nonalcoholic steatohepatitis.

Afarin, R., Hatami, M., Monjezi, S., Bineshfar, F., & Ahangarpour, A. (2024) · PubMed Central · doi:10.22038/ijbms.2024.76264.16497 · Cited by 4 · see citing works

A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis

Chávez-López, L. M., Carballo-López, G. I., Lugo-Ibarra, K. C., & Castro-Ceseña, A. B. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00420e · Cited by 3 · see citing works

Metabolic‐Associated Steatotic Liver Disease: From Molecular Mechanisms to Novel Therapies

Cooper, J., Patel, P., Tristeza, J., & Yang, A. (2025) · International Journal of Hepatology · doi:10.1155/ijh/5580454 · Cited by 3 · see citing works

Emerging Combination of Saroglitazar and Vitamin E for the Treatment of NAFLD and NASH

Tavaglione, F., & Loomba, R. S. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.101449 · Cited by 3 · see citing works

Emerging multi-target strategies and dual agonists of PPAR-α/γ modulation in Type 2 diabetes

Arora, P., Tyagi, A., Kumar, V., Arulsamy, S., Kaushik, M., & Kumar, S. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.146281 · Cited by 2 · see citing works

Nonalcoholic Steatohepatitis, Peroxisome Proliferator-Activated Receptors and Our Good Glitazar: Proof of the Pudding is in the Eating.

Anand, A. C., & Acharya, S. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.01.008 · Cited by 2 · see citing works

Clinical Case Series on Assessment of Therapeutic Efficacy of Saroglitazar in MASLD Patients

Dang, N., & Wairokpam, T. (2024) · Asian Journal of Medicine and Health · doi:10.9734/ajmah/2024/v22i91085 · Cited by 2 · see citing works

In Silico Analysis of Saroglitazar and Ferulic Acid Binding to Human Ketohexokinase: Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Tiwari, K., Kumar, B., Tiwari, A., Dhamija, P., Vardhan, G., Dehade, A., & Kumar, V. (2025) · Cureus · doi:10.7759/cureus.79437 · Cited by 2 · see citing works

Therapeutic outcome of Saroglitazar, a peroxisome proliferator activated receptor α/γ agonist in diabetic and non-diabetic metabolic dysfunction associated steatotic liver disease

Shah, N. A., Paul, S., Parveen, S., Bhat, M. H., Ali, I., & Kadla, S. A. (2025) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20251836 · Cited by 1 · see citing works

Pharmacotherapy in metabolic-dysfunction-associated steatotic liver disease: an updated review of the past, present and a promising future

Mondal, S., Chowdhury, A. S., Deb, R., & Sanyal, D. (2025) · Diabetology International · doi:10.1007/s13340-025-00833-x · Cited by 1 · see citing works

Saroglitazar for non-obese metabolic-dysfunction associated steatotic liver disease (MASLD): An open-label randomised controlled trial

Bhagat, N., De, A., Duseja, A. K., Ganesh, C. P., Kumar, M., Mehta, M., Taneja, S., Sahni, N., & Singh, V. (2026) · The Indian Journal of Medical Research · doi:10.25259/ijmr_2953_2025 · Cited by 1 · see citing works

Diallyl trisulfide attenuates metabolic syndrome via integrated modulation of PCSK-9/LDL-R axis, redox homeostasis, and inflammatory cytokine networks in high-carbohydrate high-fat (HCHF) diet-fed rats

Ahmad, P., Shah, A., Alvi, S. S., Chaturvedi, C. P., Ahmad, S., Sheeha, B. H. B., Puri, P., Alothamali, O. W., & Khan, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1781950 · Cited by 1 · see citing works

Spatial transcriptome mapping identifies Ppara-Anxa2 cross-talk in microplastic-induced hepatotoxicity

Jung, W., Abushukair, H. M., Patil, N. Y., Ampadu, F. A., Firouzi, M., Rus, I., Choi, J. S., Muthukrishnan, S. D., Shukla, S. K., Tarantini, S., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec8681 · Cited by 1 · see citing works

Comparative Efficacy of Saroglitazar and Pioglitazone in Nonalcoholic Fatty Liver Disease Patients: A Bayesian Network Meta-analysis

Sinha, B., Ghosal, S., & Datta, D. (2024) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_10_24 · Cited by 1 · see citing works

Saroglitazar - A novel treatment for non-alcoholic steatohepatitis

Noorani, S., Ankam, M., Ganesh, C. H. S. V., Banu, R., Vani, P., Polarapu, N., Jangra, S., Shaima, K. A., & Bhyan, B. (2024) · AIP conference proceedings · doi:10.1063/5.0228900 · Cited by 1 · see citing works

Saroglitazar Versus Simvastatin for Metabolic and Alcohol-Associated Liver Disease (MetALD)

Kulkarni, A. V., Gangdany, Z. M., Ramagundam, R., Sharma, M., & Padaki, N. R. (2025) · Cureus · doi:10.7759/cureus.85652 · Cited by 1 · see citing works

Nonalcoholic Fatty Liver Disease

Wadhwa, R. P., Gosavi, D. S., & Ravindranath, A. (2021) · APIK Journal of Internal Medicine · doi:10.4103/ajim.ajim_59_20 · Cited by 1 · see citing works

Utility of HS-CRP as an add on to Lipid Profile for Cardiovascular Risk Stratification in Adults with Type II Diabetes Mellitus

Din, I.-U., Batool, T., Raza, S. H., Alard Yasir, M., Salam, R. A., & Akhtar, N. (2023) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2023171442

The SVIN-Trial—Just Another Brick in the Wall?

Mehtani, R. (2024) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2024.102449

The Effect of Liv.52 DS in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): A Pilot, Randomized, Double-Blind, Placebo-Controlled, Clinical Study

Jalihal, U., Nanda, R., Katariya, K., Balamurugan, R., & Kumawat, R. (2025) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s527644

Metabolic Comorbidities Modulate the Impact of Weight Loss on Liver Fibrosis in MASLD: A Real World Prospective Cohor StudyPreprint

Yang, A., Zhu, X., Zhang, L., Lv, G., & Ding, Y. (2025) · Research Square · doi:10.21203/rs.3.rs-6314701/v1

Impact of Saroglitazar on Liver Stiffness Measurements in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) With Compensated Cirrhosis: A Single-Arm Study

Roy, A., Chakraborty, S., Jajodia, S., Goenka, U., Tewari, A., Sonthalia, N., Ghoshal, U. C., & Goenka, M. K. (2025) · Cureus · doi:10.7759/cureus.92313

Effect of Addition of Saroglitazar to Lifestyle Modifications in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Observational Study

Ragottham, K., Mukunda, N., & Lokesh, L. V. (2025) · Annals of African Medicine · doi:10.4103/aam.aam_454_25

Implication of the Androgen Receptor in Muscle–Liver Crosstalk: An Overlooked Mechanistic Link in Lean-MASLD

Trifylli, E.-M., Charalambous, C. H., Spiliotopoulos, N., Papadopoulos, N., Oikonomou, A., Manolakopoulos, S., & Deutsch, M. J. (2025) · Livers · doi:10.3390/livers5040065

Role of Saroglitazar in Improving Transient Elastography Parameters in Significant and Advanced Metabolic Dysfunction-Associated Steatohepatitis

Kak, M. (2025) · Cureus · doi:10.7759/cureus.99044

Effect of Saroglitazar on Glycemic Status: A Meta-analysis

Selvarajan, S., Anandabaskar, N., Jayakumar, I., Venkatraman, S., Shivabasappa, S., Sahoo, J., Kamalanathan, S., & George, M. (2025) · Cureus · doi:10.7759/cureus.99122

A Comparative Evaluation of the Effects of Saroglitazar and Pioglitazone on Hepatic and Metabolic Parameters in Type 2 Diabetes Mellitus With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Meher, D., DAS, S., Choudhury, A. K., Sahoo, D., Sahu, S. K., Agarwal, V., Prusty, B., Das, B. K., Chappalagavi, A. S., Gupta, S., et al. (2025) · Cureus · doi:10.7759/cureus.100002

Effectiveness and Safety of Saroglitazar in Patients With Metabolic Disease in India Stratified by Estimated Glomerular Filtration Rate (eGFR): A Retrospective, Observational, Electronic Medical Record (EMR)-Based Real-World Evidence Study

Tripathi, K., Chafekar, D. S., Verma, H., Bantwal, G., Shah, P., Bhattacharya, S., Sahay, M., Golay, V., Shanmugraj, G., Awasthi, R., et al. (2026) · Cureus · doi:10.7759/cureus.105083

Saroglitazar and vitamin E vs . lifestyle interventions in metabolic dysfunction associated steatotic liver disease: A 3-arm randomised study

Tiwari, A. K., Singh, G., Kumar, V., Yadav, D. P., Shukla, S. K., Singh, V., Mishra, G., Tiwary, N. K., Anunay, A., Singh, D., et al. (2026) · The Indian Journal of Medical Research · doi:10.25259/ijmr_2511_2025

Pharmacologic management of metabolic and alcohol-associated liver disease

Pagadala, M., Jalil, S., Dunn, N., & Singal, A. K. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.29

Metabolic Benefits of Saroglitazar 4 mg in Type 2 Diabetes Mellitus With Dyslipidemia: A Retrospective Real-World Observational Cohort Study From India

Jagadeesha, A., Bhattacharya, S., SHRIVASTAVA, A., Samajdar, S. S., Gunjan, G., Bhardwaj, S., & TELANG, S. (2026) · Cureus · doi:10.7759/cureus.111328

Efficacy of Dapagliflozin vs. Saroglitazar on Hepatic Steatosis and Fibrosis in Patients of Type 2 Diabetes Mellitus and Metabolic-Associated Steatotic Liver Disease (MASLD)

Das, B. K., Das, S., Meher, D., Choudhury, A. K., Padhee, S., Sahu, S. K., Sahoo, D., Prusty, B., & Agarwal, V. (2026) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_848_25

Safety and Efficacy of Moringa oleifera Lam Supplementation in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease: A Prospective Real-world Study from Bangladesh

Akhand, M. S., Noor-E-Alam, S. M., Rahim, M. A., Karim, R., Hasan, M. R., Karmakar, D., Mondal, D. K., Sopan, N. T., Jalal, J. B., Arafat, M. A., et al. (2026) · Journal of Indian System of Medicine · doi:10.5005/jism-11051-0050

Saroglitazar Facilitates Insulin De-escalation and Improves Metabolic Parameters in Pioglitazone-Ineligible Non-metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Type 2 Diabetes: Real-World Evidence From India

Kuberan, I. (2026) · Cureus · doi:10.7759/cureus.117669

1034 Efficacy and Safety of Saroglitazar in Nonalcoholic Fatty Liver Disease Patients at 1 Year: An Investigator Initiated Study

Dadhich, S. (2019) · The American Journal of Gastroenterology · doi:10.14309/01.ajg.0000593672.52086.e9 · Cited by 3 · see citing works

Safety and Efficacy of Saroglitazar in Nonalcoholic Fatty Liver Patients With Diabetic Dyslipidemia—A Prospective, Interventional, Pilot Study

Rajesh, N., Drishya, L., Ambati, M. M. R., Narayanan, A. L., Alex, M., Rathinam, K. K., Abraham, J. J., & Vijayakumar, T. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.03.012 · Cited by 29 · see citing works

Role of Saroglitazar in Non Diabetic Non Alcoholic Fatty Liver Disease Patients: A Retrospective Observational Study

Jaiswal, A., Jain, K., & Singh, A. (2021) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2021/52065.15738 · Cited by 3 · see citing works

Efficacy and safety of saroglitazar in real‐world patients of non‐alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience

Chaudhuri, S., Dutta, A., & Chakraborty, S. B. D. (2023) · JGH Open · doi:10.1002/jgh3.12878 · Cited by 38 · see citing works

Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients

Padole, P., Arora, A., Sharma, P., Chand, P., Verma, N., & Kumar, A. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.06.015 · Cited by 28 · see citing works